Resumption of trastuzumab in patients with disease recurrence after (Neo-) adjuvant anti-HER2-therapy in patients with HER2-positive breast cancer

Lars Christian Hanker*, Frank Förster, Jan Schröder, Andrea Grafe, Thomas Hitschold, Tobias Hesse, Claus Richard Lattrich, Achim Rody

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Background/Aim: HER2-positive breast cancers eventually relapse in about one third of patients. Is anti-HER2- directed therapy with Herceptin® (trastuzumab) effective in retreatment? Between 2008 and 2018, 216 patients with recurrent HER2-positive breast cancer (BC) were re-treated with Herceptin (HER) during first-line therapy. This study assessed the effectiveness and tolerability of re-treatment with HER. Patients and Methods: After approval from Ethical committee, the NIS was conducted according to German Drug Act. Retreatment with HER was documented at routine visits starting with a basic observational period of maximum 12 months and a follow-up period of maximum additional four years. Results: HER2-positive BC relapsed after a median of 36.5 months (mos). Patients were re-treated with HER +/- chemotherapy +/- endocrine therapy. HER-containing regimens resulted in median progression-free survival (mPFS) of 12.7 (95%CI=10.5- 14.8) mos and overall survival (OS-2) of 31.6 mos (95%CI=28.8-38.4) since recurrence diagnosis. Differentiation of recurrence types (local, visceral, non-visceral) unfolded worst prognosis for patients with visceral metastases. Cardiac monitoring within this non-interventional study (NIS) did not result in new safety concerns. Conclusion: Re-therapy with HER in the first-line setting of advanced HER2-positive breast cancer is effective and without unexpected or intensified adverse events.

OriginalspracheEnglisch
ZeitschriftAnticancer Research
Jahrgang40
Ausgabenummer7
Seiten (von - bis)3973-3981
Seitenumfang9
ISSN0250-7005
DOIs
PublikationsstatusVeröffentlicht - 07.2020

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)
  • Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Resumption of trastuzumab in patients with disease recurrence after (Neo-) adjuvant anti-HER2-therapy in patients with HER2-positive breast cancer“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren